[1]杨年欢,袁国盛,周宇辰,等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效[J].南方医科大学学报,2016,(06):775.
点击复制

恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效()
分享到:

《南方医科大学学报》[ISSN:/CN:]

卷:
期数:
2016年06期
页码:
775
栏目:
出版日期:
2016-06-20

文章信息/Info

Title:
Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses
作者:
杨年欢袁国盛周宇辰刘俊维黄华萍胡承光熊玲李园周福元杨淑玲周元平
关键词:
乙型肝炎肝纤维化恩替卡韦复方鳖甲软肝片联合
Keywords:
hepatitis B chronic liver fibrosis entecavir Fufang Biejia Ruangan tablet combination
摘要:
目的观察恩替卡韦联合复方鳖甲软肝片对慢性乙型肝炎(CHB)肝纤维化患者的临床疗效,探索具有协同治疗作用、促进 CHB肝纤维化逆转的联合治疗方案。方法2010 年6 月~2015 年6 月在南方医科大学南方医院感染内科接受抗病毒治疗的 CHB肝纤维化患者197例构成随访队列,按年龄、性别、LSM配对后分为恩替卡韦联合复方鳖甲软肝片组(以下简称A组,n=98 例)和单用恩替卡韦治疗组(以下简称B组,n=99例),每12周随访1次。检测两组患者HBV DNA定量、血清学指标、血生化指 标,肝脏硬度值(LSM)采用FibroScan检测,并转换为Metavir分期。结果治疗后两组患者LSM均明显降低(P<0.05),A组与B 组Metavir分级下降中位时间分别为72周、96周,差异有统计学显著性意义;A组和B组ALT复常中位时间分别为12周、24周, AST复常中位时间分别为24周、36周,差异均有统计学显著性意义。两组HBV DNA阴转率、HBeAg血清学转换率无明显差 异。结论恩替卡韦联合复方鳖甲软肝片能进一步改善CHB肝纤维化患者的总体疗效;对CHB肝纤维化具有协同治疗效应;复 方鳖甲软肝片尚具有独立的护肝降酶作用。
Abstract:
Objective To evaluate the effect of long-term therapy with entecavir and Fufang Biejia Ruangan tablet in patients with chronic hepatitis B (CHB)-associated fibrosis and explore the synergistic therapy that accelerates the reversion of liver fibrosis. Methods A total of 197 patients with CHB-associated fibrosis were recruited from Nanfang Hospital between June, 2010 and June, 2015. The patients were divided into two groups after matching for age, gender and liver stiffness measurement (LSM), namely group A (n=98) treated with Fufang Biejia Ruangan Tablet plus entecavir, and group B (n=99) to receive entecavir only. HBV DNA quantification, HBV serological indicators, blood biochemical indexes, and results of abdominal ultrasound and FibroScan were recorded every 12 weeks. FibroScan values were converted to Metavir staging. Results Both groups showed significant decreases in serum levels of HBV DNA, alanine aminotransferase (ALT), and LSM value from baseline (all P<0.05). The median time to achieve Metavir fibrosis staging improvement were 72 weeks in group A and 96 weeks in group B (P<0.05), and the median time to achieve ALT and AST normalization were 12 and 24 weeks in Group A, respectively, significantly shorter than the time in group B (P<0.05). No significant difference was found between the two groups in HBV DNA undetectable rate and HBeAg seroconversion rate. Conclusion The combination therapy with Fufang Biejia Ruangan tablet and entecavir produces a stronger efficacy than entecavir alone in the treatment of chronic hepatitis B patients with liver fibrosis, and Fufang Biejia Ruangan tablet shows an obvious hepatoprotective effect in these patients.

相似文献/References:

[1]刘刚,卢光琇. 湖南汉族人群CTLA4 基因+49G/A 多态性与乙肝感染和乙肝源性肝癌相关性的初步研究[J].南方医科大学学报,2010,(08):1838.
 LIU Gang,LU Guang-xiu.Association of CTLA4 gene +49G/A polymorphism with HBV infection and HBV-relatedhepatocellular carcinoma in Hunan Han population[J].,2010,(06):1838.
[2]梁建新,屈杏芬,曾文铤,等. 氧化苦参碱在治疗慢性乙型肝炎中抗肝纤维化的作用机制[J].南方医科大学学报,2010,(08):1871.
 LIANG Jian-xin,QU Xing-fen,ZENG Wen-ting,et al.Mechanism of oxymatrine in preventing hepatic fibrosis formation in patients with chronic hepatitis B[J].,2010,(06):1871.
[3]李新瑜,熊伟,韩路军,等.核磁共振动态增强成像评价肝纤维化的临床应用[J].南方医科大学学报,2011,(07):1259.
[4]黄亮,漆林艳,陈志良,等.复方抗肝纤维化处方的优化[J].南方医科大学学报,2012,(01):106.
[5]黄珊,张文雍,潘春球,等.胆管结扎诱导的肝纤维化大鼠肝脏上皮间质表型的变化[J].南方医科大学学报,2012,(02):173.
[6]赵金红,王健,江水清,等.慢性乙型肝炎患者CXC趋化因子Mig的表达[J].南方医科大学学报,2006,(11):1589.
 ZHNA Jin-hong,WANG Jian,JIANG Shui-qing,et al.Expression of chemokine monokine induced by interferon-γ in patients with chronic hepatitis B[J].,2006,(06):1589.
[7]樊和斌,郭亚兵,杨洁,等.慢性乙型肝炎患者HBV基因型及其临床意义[J].南方医科大学学报,2005,(02):229.
 FAN He-bin,GUO Ya-bing,YANG Jie,et al.Genotyping of hepatitis B virus and its clinical significance in patients with chronic hepatitis B[J].,2005,(06):229.
[8]李旭,宁佐伟,罗薇,等.腹腔持续注射血管紧张素-(1-7)对胆管结扎大鼠肝纤维化的抑制作用[J].南方医科大学学报,2012,(07):944.
[9]李旭,蔡双明,宁佐伟,等.螺内酯对肝纤维化大鼠肝窦血管生成的抑制作用[J].南方医科大学学报,2012,(08):1135.
[10]张莉莉,张文雍,李洋,等.慢病毒介导ACE2过表达对血管紧张素Ⅱ诱导的大鼠肝细胞的白蛋白表达及迁移能力的影响[J].南方医科大学学报,2015,(05):652.
[11]于宏,曹治宸,耿建英,等.干扰素α治疗慢性乙型肝炎患者肝纤维化的实验研究[J].南方医科大学学报,2005,(11):1409.
 YU Hong,CAO Zhi-chen,GENG Jian-ying,et al.Effect of interferon alpha on liver fibrosis in patients with chronic hepatitis B[J].,2005,(06):1409.

更新日期/Last Update: 1900-01-01